The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
Christina Antza,1,* Krishnarajah Nirantharakumar,2,* Ioannis Doundoulakis,3 Abd A Tahrani,4–6 Konstantinos A Toulis2,313rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece; 2Institute of Applied Health Research, University of Birmingham, Bi...
Main Authors: | Antza C, Nirantharakumar K, Doundoulakis I, Tahrani AA, Toulis KA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-08-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/the-development-of-an-oral-glp-1-receptor-agonist-for-the-management-o-peer-reviewed-article-DDDT |
Similar Items
-
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01) -
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
by: Jiani Zhong, et al.
Published: (2024-05-01) -
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
by: Ji Hee Yu, et al.
Published: (2022-03-01) -
GLP-1 receptor agonist as a modulator of innate immunity
by: Jun Chen, et al.
Published: (2022-12-01) -
GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
by: Ahlima Roumane, et al.
Published: (2024-04-01)